2seventy bio Reiterates Commitment to Maximizing Shareholder Value
06 Décembre 2023 - 8:00PM
Business Wire
2seventy bio, Inc. (NASDAQ: TSVT), (“2seventy” or “the
Company”), a leading immuno-oncology cell therapy company, today
issued the following statement reiterating its commitment to
maximizing shareholder value:
As we indicated last month, the Board has
commenced a process to consider all options to maximize value. This
process is well underway and our team is committed to working as
thoughtfully and quickly as possible to ensure our important
therapies become available to patients in need, we drive value for
our shareholders and best support our employees.
About 2seventy bio
Our name, 2seventy bio, reflects why we do what we do - TIME.
Cancer rips time away, and our goal is to work at the maximum speed
of translating human thought into action – 270 miles per hour – to
give the people we serve more time. We are building the leading
immuno-oncology cell therapy company, focused on discovering and
developing new therapies that truly disrupt the cancer treatment
landscape.
With a deep understanding of the human body’s immune response to
tumor cells and how to translate cell therapies into practice,
we’re applying this knowledge to deliver next generation cellular
therapies that focus on a broad range of hematologic malignancies,
including the first FDA-approved CAR T cell therapy for multiple
myeloma, as well as solid tumors. Our research and development is
focused on delivering therapies that are designed with the goal to
“think” smarter and faster than the disease. Importantly, we remain
focused on accomplishing these goals by staying genuine and
authentic to our “why” and keeping our people and culture top of
mind every day.
For more information, visit www.2seventybio.com.
Follow 2seventy bio on social media: X (Twitter) and
LinkedIn.
Forward-Looking Statements
This release contains “forward-looking statements” within the
meaning of applicable laws and regulations. These statements
include, but are not limited to, statements concerning our process
to consider all options to maximize value. Any forward-looking
statements in this press release are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, our ability to successfully execute
on our evaluation of value-maximizing options and on any resulting
strategic or other related actions. For a discussion of other risks
and uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in our annual report on Form 10-K for the year ended December 31,
2022 and our quarterly report on Form 10-Q for the quarter ended
September 30, 2023, as supplemented and/or modified by our most
recent Quarterly Report on Form 10-Q and any other filings that we
have made or will make with the Securities and Exchange Commission
in the future. All information in this press release is as of the
date of the release, and 2seventy bio undertakes no duty to update
this information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231206910473/en/
Investors: Elizabeth Pingpank Hickin, 860-463-0469
Elizabeth.pingpank@2seventybio.com
Media: Jenn Snyder, 617-448-0281
Jenn.snyder@2seventybio.com
Morgan Adams Shields, 774-313-9852
morgan.adams@2seventybio.com
2seventy bio (NASDAQ:TSVT)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
2seventy bio (NASDAQ:TSVT)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024